Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: rjk01 who wrote (5511)	10/4/2012 7:35:06 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

My gut feeling was that they'd do the split as well, however I listened to others believing they'd wait, they were wrong. As for the R/S if the news afterwords is good, AEZS could easily reach $10, which still would be nearly a double for me. Tomorrow it will trade at something over $3, I'm even at over $5 and would have actually been slightly ahead had a sold at recent highs. While I don't agree with the actions of the BOD, I still believe the company is dramatically underpriced given all the products they have in, approaching, or completed Pivotal Trials. The company didn't fail to get fast track, they failed to get fast track with a rolling review permitting them to file only the first part of the NDA. Once the NDA's complete, they can file it requesting fast track, or is it Priority Review, but they must submit the entire document. This creates no more than a 4 month delay as the FDA does nothing in under 60 days, so the last part of the NDA would have to have been filed 4 months after the first part if the PFUDA date wouldn't be delayed. From a standpoint of a partnership for AEZS-130, this delay should permit the completion of the Cancer Cachexia trial prior to an FDA decision. If the results of this trial are positive, the value of AEZS-130 in a partnership might be hundreds to thousands of times more valuable as a Niche drug would suddenly have Blockbuster potential. Remember, there is currently no approved product for Cancer Cachexia, and many die prematurely from weight loss weakening vital organs before the cancer takes them. I believe this drug is truly the joker in AEZS's pipeline, it clearly should gain approval for detecting HGH deficiency, the only other drug approved for this has been removed from the market by its maker, and with neither of them, I gather around the clock blood sampling is the only way of being sure. I believe AEZS-130 was a far simpler and less expensive way of making this determination, it was just as accurate, and the maker of the other product saw the handwriting on the wall. It created a problem as the trial which originally used the other drug in the control group had to be redesigned. A partnership will certainly be needed to expand use beyond the U.S. but the value of such a partnership will be greatly determined by whether Cancer Cachexia trials demonstrate see benefits. Gary